dichlororibofuranosylbenzimidazole and gw 257406x

dichlororibofuranosylbenzimidazole has been researched along with gw 257406x in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	5 (100.00)	2.80

Authors

Authors	Studies
Alain, S; Alexander, BD; Avery, RK; Blumberg, EA; Chemaly, RF; Cordonnier, C; Duarte, RF; Florescu, DF; Fournier, M; Kamar, N; Kumar, D; Maertens, J; Marty, FM; Papanicolaou, GA; Silveira, FP; Sundberg, AK; Witzke, O; Wu, J	1
Hedvat, J; Lange, NW; Sabatino, DC; Salerno, DM	1
Blumberg, EA; Halpern-Cohen, V	1
Ilic, K; Song, I; Suttle, B; Wu, J	1

Reviews

1 review(s) available for dichlororibofuranosylbenzimidazole and gw 257406x

Article	Year
New Perspectives on Antimicrobial Agents: Maribavir. Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9 Topics: Adult; Anti-Infective Agents; Antiviral Agents; Benzimidazoles; Child; Cidofovir; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; Valganciclovir	2022

Trials

2 trial(s) available for dichlororibofuranosylbenzimidazole and gw 257406x

Article	Year
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4 Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; Valganciclovir; Viremia	2022
Pharmacokinetics and Safety Evaluation of Maribavir in Healthy Japanese and Matched White Participants: A Phase 1, Open-Label Study. Clinical pharmacology in drug development, 2023, Volume: 12, Issue:6 Topics: Adult; Antiviral Agents; Area Under Curve; Dichlororibofuranosylbenzimidazole; East Asian People; Humans; White People	2023

Article

Year

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4

Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; Valganciclovir; Viremia

2022

Pharmacokinetics and Safety Evaluation of Maribavir in Healthy Japanese and Matched White Participants: A Phase 1, Open-Label Study.

Clinical pharmacology in drug development, 2023, Volume: 12, Issue:6

Topics: Adult; Antiviral Agents; Area Under Curve; Dichlororibofuranosylbenzimidazole; East Asian People; Humans; White People

2023

Other Studies

2 other study(ies) available for dichlororibofuranosylbenzimidazole and gw 257406x

Article	Year
Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients. Transplant infectious disease : an official journal of the Transplantation Society, 2022, Volume: 24, Issue:4 Topics: Benzimidazoles; Dichlororibofuranosylbenzimidazole; Humans; Immunosuppressive Agents; Organ Transplantation; Ribonucleosides; Tacrolimus; Transplant Recipients	2022
Maribavir (Livtencity) for cytomegalovirus infection. The Medical letter on drugs and therapeutics, 2022, 11-28, Volume: 64, Issue:1664 Topics: Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; Humans	2022